-
Je něco špatně v tomto záznamu ?
Novel Splicing Variant in the PMM2 Gene in a Patient With PMM2-CDG Syndrome Presenting With Pericardial Effusion: A Case Report
K. Slaba, H. Noskova, P. Vesela, J. Tuckova, H. Jicinska, T. Honzik, H. Hansikova, P. Kleiblova, P. Stourac, P. Jabandziev, O. Slaby, D. Prochazkova,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
- Publikační typ
- časopisecké články MeSH
Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases with the phosphomannomutase 2 (PMM2)-CDG being the most common form of CDG. Most of these monogenic diseases are autosomal recessive and have multi-systemic manifestations, mainly psychomotor retardation, facial dysmorphisms, characteristic distribution of the fat pads, and variable coagulation abnormalities. The association of fetal hydrops with CDG has been reported, and pericardial effusion was also rarely observed in patients with PMM2-CDG. Here we describe an infant boy with PMM2-CDG. The diagnosis was suspected based on inverted nipples, fat pads, and combined coagulopathy. However, the primary symptom was progressive pericardial effusion leading to patient death at the age of 3 months. Screening for CDG performed by the use of isoelectric focusing of serum transferrin showed a typical PMM2-CDG pattern. Exome sequencing revealed one common pathogenic variant (c.691G > A/p.Val231Met) and one novel variant (c.447 + 3dupA) in the PMM2 gene. Both PMM2 variants were further confirmed by Sanger sequencing in both the proband and the parents' DNA. The novel variant was predicted to result in loss of donor splice site, and the analysis at mRNA level confirmed that it leads to exon five skipping (r.348_447del) and causes premature termination of translation to the protein (p.G117Kfs∗4), therefore is classified as likely pathogenic. Although there is no curative therapy for the PMM2-CDG at the moment, the other supportive care options are available to be offered. The definite diagnosis of PMM2-CDG can also assist in the process of genetic counseling, family planning, and preimplantation genetic diagnosis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21002001
- 003
- CZ-PrNML
- 005
- 20210126092710.0
- 007
- ta
- 008
- 210105s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fgene.2020.561054 $2 doi
- 035 __
- $a (PubMed)33133147
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Slaba, Katerina $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
- 245 10
- $a Novel Splicing Variant in the PMM2 Gene in a Patient With PMM2-CDG Syndrome Presenting With Pericardial Effusion: A Case Report. / $c K. Slaba, H. Noskova, P. Vesela, J. Tuckova, H. Jicinska, T. Honzik, H. Hansikova, P. Kleiblova, P. Stourac, P. Jabandziev, O. Slaby, D. Prochazkova,
- 520 9_
- $a Congenital disorders of glycosylation (CDG) are a rapidly growing family of genetic diseases with the phosphomannomutase 2 (PMM2)-CDG being the most common form of CDG. Most of these monogenic diseases are autosomal recessive and have multi-systemic manifestations, mainly psychomotor retardation, facial dysmorphisms, characteristic distribution of the fat pads, and variable coagulation abnormalities. The association of fetal hydrops with CDG has been reported, and pericardial effusion was also rarely observed in patients with PMM2-CDG. Here we describe an infant boy with PMM2-CDG. The diagnosis was suspected based on inverted nipples, fat pads, and combined coagulopathy. However, the primary symptom was progressive pericardial effusion leading to patient death at the age of 3 months. Screening for CDG performed by the use of isoelectric focusing of serum transferrin showed a typical PMM2-CDG pattern. Exome sequencing revealed one common pathogenic variant (c.691G > A/p.Val231Met) and one novel variant (c.447 + 3dupA) in the PMM2 gene. Both PMM2 variants were further confirmed by Sanger sequencing in both the proband and the parents' DNA. The novel variant was predicted to result in loss of donor splice site, and the analysis at mRNA level confirmed that it leads to exon five skipping (r.348_447del) and causes premature termination of translation to the protein (p.G117Kfs∗4), therefore is classified as likely pathogenic. Although there is no curative therapy for the PMM2-CDG at the moment, the other supportive care options are available to be offered. The definite diagnosis of PMM2-CDG can also assist in the process of genetic counseling, family planning, and preimplantation genetic diagnosis.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Noskova, Hana $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
- 700 1_
- $a Vesela, Petra $u Central European Institute of Technology, Masaryk University, Brno, Czechia.
- 700 1_
- $a Tuckova, Jana $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Jicinska, Hana $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Honzik, Tomas $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
- 700 1_
- $a Hansikova, Hana $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
- 700 1_
- $a Kleiblova, Petra $u Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia.
- 700 1_
- $a Stourac, Petr $u Department of Pediatric Anaesthesiology and Intensive Care Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Jabandziev, Petr $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia. Central European Institute of Technology, Masaryk University, Brno, Czechia.
- 700 1_
- $a Slaby, Ondrej $u Central European Institute of Technology, Masaryk University, Brno, Czechia. Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czechia.
- 700 1_
- $a Prochazkova, Dagmar $u Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czechia. Institute of Medical Genetics, Faculty of Medicine, Masaryk University, Brno, Czechia.
- 773 0_
- $w MED00184539 $t Frontiers in genetics $x 1664-8021 $g Roč. 11, č. - (2020), s. 561054
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33133147 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210126092706 $b ABA008
- 999 __
- $a ind $b bmc $g 1614107 $s 1122285
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 11 $c - $d 561054 $e 20201007 $i 1664-8021 $m Frontiers in genetics $n Front Genet $x MED00184539
- LZP __
- $a Pubmed-20210105